Pathogenesis and Molecular Treatment of Primary Liver Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 57
Special Issue Editor
Special Issue Information
Dear Colleagues,
Primary liver cancer (PLC) is a group of tumor entities that are characterized by their high aggressiveness and dismal outcomes. PLC has steadily increased in incidence in recent decades and has become a significant health concern worldwide. Histologically, PLC mainly consists of hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA) in adulthood, and hepatoblastoma (HBL) in childhood. Due to its asymptomatic nature in the early phases of the disease, PLC is generally diagnosed when the tumor is inoperable, and systemic treatments have limited efficacy. Therefore, a better understanding of the molecular pathogenesis of PLC is imperative to improve patients’ outcomes. In recent years, numerous signaling cascades involved in PLC development and progression have been elucidated, and several molecularly and immunologically based therapies have been generated, with some becoming the first-line treatment for specific tumor subsets.
Given PLC’s importance in the medical and research fields, the International Journal of Molecular Sciences is launching this Special Issue.
Specifically, we aim to showcase the current knowledge on the molecular pathogenesis of PLC and the efforts on anticancer drug development. Original research articles, review articles, and short communications within the described research topic are welcome.
Dr. Diego F. Calvisi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- primary liver cancer
- cholangiocarcinoma
- hepatocellular carcinoma
- hepatoblastoma
- molecular pathogenesis
- targeted therapies
- anticancer drug
